100 Cambridgepark Drive, Suite 101

Cambridge, MA 02140

December 16, 2022


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn:    Jason Drory
Re:    Vor Biopharma Inc.
   Registration Statement on Form S-3 (File No. 333-268798)
   Request for Acceleration of Effective Date
   Acceleration Request
            Requested Date:    December 20, 2022
            Requested Time:    4:00 p.m. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-268798) (theRegistration Statement”) to become effective on December 20, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Katie Kazem at (703) 456-8043.

[Signature page follows]

Very truly yours,
Vor Biopharma Inc.

/s/ Robert Ang

  Robert Ang
  Chief Executive Officer and Director


  Robert Ang, Vor Biopharma Inc.

Nathan Jorgensen, Vor Biopharma Inc.

Divakar Gupta, Cooley LLP

Katie Kazem, Cooley LLP

Signature Page to Company Acceleration Request – S-3